Empagliflozin -- kidney protection regardless of an initial 'eGFR dip'

(ERA-EDTA) Data presented today at the ERA-EDTA Congress show that empagliflozin is more likely to induce an initial 'dip' in eGFR in patients belonging to a higher KDIGO risk category and/or on diuretic therapy. However, this did not impact the rate of adverse events or kidney outcomes. For these patients, especially, any intervention is welcome that slows the progression of kidney disease and allows the need for dialysis to be postponed as long as possible.